ENTITY
Lee's Pharmaceutical

Lee's Pharmaceutical (950 HK)

17
Analysis
Health CareHong Kong
Lee's Pharmaceutical Holdings Limited develops, manufactures and sells quality biopharmaceutical products that focus on combating cardiovascular diseases and viral sexually transmitted diseases.
more
Refresh
28 Mar 2024 22:13

SciClone Pharma (6600 HK): GL Capital’s Scheme Offer at HK$18.80

The offer price has been declared final. It is reasonable, aligning with the all-time high and the IPO price. This is a done deal.

Logo
221 Views
Share
19 Mar 2024 17:27

SciClone Pharma (6600 HK): Privatisation Déjà Vu All over Again?

A GL Capital-led consortium will likely once again lead the privatisation. An offer price at or slightly above the IPO price (HK$18.80) would be...

Logo
236 Views
Share
16 Apr 2021 17:20

Zhaoke Ophthalmology IPO: Valuation Insights

Zhaoke has launched an HKEx IPO to raise net proceeds of $239m at the mid-point of the IPO price range of HK$15.38-16.80 per share. Overall, we...

Logo
463 Views
Share
12 Apr 2021 18:57

Zhaoke Ophthalmology IPO Initiation: The Eyes Have It

Zhaoke is pre-marketing an HKEx IPO to raise $200 million, according to press reports. Overall, we believe that Zhaoke’s drug assets are attractive.

Logo
330 Views
Share
06 Apr 2021 11:03

Zhaoke Ophthalmic (兆科眼科) Pre-IPO: Thoughts on Valuation

In this note, we provide a forecast on Zhaoke Ophthalmic's two core products CsA ophthalmic gel and the ZKY001 and an SOTP based valuation for the...

Logo
377 Views
Share
x